MDT

100.38

-0.29%↓

A

133.77

-1.36%↓

VEEV

217.07

-0.91%↓

HQY

82.72

-0.62%↓

NEOG

10.33

-0.67%↓

MDT

100.38

-0.29%↓

A

133.77

-1.36%↓

VEEV

217.07

-0.91%↓

HQY

82.72

-0.62%↓

NEOG

10.33

-0.67%↓

MDT

100.38

-0.29%↓

A

133.77

-1.36%↓

VEEV

217.07

-0.91%↓

HQY

82.72

-0.62%↓

NEOG

10.33

-0.67%↓

MDT

100.38

-0.29%↓

A

133.77

-1.36%↓

VEEV

217.07

-0.91%↓

HQY

82.72

-0.62%↓

NEOG

10.33

-0.67%↓

MDT

100.38

-0.29%↓

A

133.77

-1.36%↓

VEEV

217.07

-0.91%↓

HQY

82.72

-0.62%↓

NEOG

10.33

-0.67%↓

Search

VistaGen Therapeutics Inc

Abierto

0.58 -3.33

Resumen

Variación precio

24h

Actual

Mínimo

0.58

Máximo

0.6

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+51.56% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 feb 2026

VistaGen Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 ene 2026, 23:07 UTC

Ganancias

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 ene 2026, 21:27 UTC

Ganancias

Texas Instruments 4Q Sales Rise, Profit Falls

27 ene 2026, 23:55 UTC

Charlas de Mercado

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 ene 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 ene 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 ene 2026, 23:39 UTC

Charlas de Mercado

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 ene 2026, 23:20 UTC

Ganancias

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 ene 2026, 23:20 UTC

Ganancias

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 ene 2026, 23:19 UTC

Ganancias

SK Innovation Posts Net Loss for Second Consecutive Year

27 ene 2026, 23:19 UTC

Ganancias

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 ene 2026, 23:18 UTC

Ganancias

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 ene 2026, 23:18 UTC

Ganancias

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 ene 2026, 23:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 ene 2026, 23:11 UTC

Charlas de Mercado

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 ene 2026, 23:07 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 ene 2026, 22:17 UTC

Charlas de Mercado

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 ene 2026, 22:06 UTC

Ganancias

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 ene 2026, 21:51 UTC

Ganancias

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 ene 2026, 21:43 UTC

Ganancias

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 ene 2026, 21:41 UTC

Ganancias

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 ene 2026, 21:38 UTC

Ganancias

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 ene 2026, 21:32 UTC

Ganancias

Ampol: Modest Profit From F&I International in 2025

27 ene 2026, 21:32 UTC

Ganancias

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 ene 2026, 21:31 UTC

Ganancias

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 ene 2026, 21:31 UTC

Ganancias

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 ene 2026, 21:30 UTC

Ganancias

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 ene 2026, 21:29 UTC

Ganancias

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 ene 2026, 21:29 UTC

Ganancias

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 ene 2026, 21:28 UTC

Ganancias

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Comparación entre iguales

Cambio de precio

VistaGen Therapeutics Inc previsión

Precio Objetivo

By TipRanks

51.56% repunte

Estimación a 12 Meses

Media 0.97 USD  51.56%

Máximo 1 USD

Mínimo 0.9 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para VistaGen Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

0

Comprar

5

Mantener

0

Vender

Finanzas

$

help-icon Live chat